Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Alnylam Pharmaceuticals Inc.
said Monday it would no longer pursue its supplemental new drug application for patisiran as a treatment for the cardiomyopathy of transthyretin-mediated amyloidosis after receiving a complete response letter from the U.S. Food and Drug Administration. Patisiran is already approved for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults. The CRL, which means the FDA cannot approve the sNDA for now, does not impact the other indication.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Best Buy to start offering a continuous glucose monitoring system for diabetics, it’s first prescription-based medical deviceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
続きを読む »
ABC 10News Pinpoint Weather for Sun. October 8, 2023: Foggy start along the coast, cool down on the wayCiara Encinas joined the ABC 10News team in December 2021 as a multimedia journalist.
続きを読む »
ABC 10News Pinpoint Weather for Sat. October 7, 2023: Foggy start along coast, another warm day inlandCiara Encinas joined the ABC 10News team in December 2021 as a multimedia journalist.
続きを読む »
The Best Beauty Instagrams of the Week: Ciara, Troye Sivan, and MoreThis week's best beauty Instagrams presented glamour in all forms.
続きを読む »
FDA-approved injection can restore collagen and improve aging signsThe Food and Drug Administration has approved an easy and effective method of restoring collagen in the skin without having to ingest endless supplements.
続きを読む »
FDA: Blood Pressure Medication Recall After Oxycodone FoundI am a writer, journalist, professor, systems modeler, computational, AI, and digital health expert, medical doctor, avocado-eater, and entrepreneur, not always in that order. Currently, I am a Professor of Health Policy and Management at the City University of New York (CUNY) School of Public Health, Executive Director of PHICOR (PHICORteam) and Center for Advanced Technology and Communication in Health (CATCH), and founder and CEO of Symsilico. My previous positions include serving as Profess
続きを読む »